Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64. doi: 10.1097/QAI.0b013e3182084b5a.

2.

Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.

Messou E, Chaix ML, Gabillard D, Yapo V, Toni TD, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):211-9. doi: 10.1097/QAI.0b013e3182a009e4.

3.

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.

Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, Eholié SP, Maylin S, Delaugerre C, Zoulim F, Girard PM, Lacombe K; ANRS 12240 VarBVA study.

Antivir Ther. 2015;20(6):643-54. doi: 10.3851/IMP2959. Epub 2015 Apr 8.

PMID:
25852125
4.

HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.

Hanson DL, Adjé-Touré C, Talla-Nzussouo N, Eby P, Borget MY, Kouadio LY, Celestin BE, Tossou O, Eholie S, Kadio A, Chorba T, Nkengasong JN.

AIDS Res Hum Retroviruses. 2009 May;25(5):489-95. doi: 10.1089/aid.2008.0273.

PMID:
19388820
5.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
6.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E, Chaix ML, Peeters M, Ayouba A; ANRS 12186 Study Group.

Clin Infect Dis. 2014 Jan;58(1):99-109. doi: 10.1093/cid/cit627. Epub 2013 Sep 27.

PMID:
24076968
7.

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.

Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

Antivir Ther. 2003 Oct;8(5):385-93.

PMID:
14640385
8.

Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, Fassinou P, Bissagnene E, Kadio A, Nolan ML, Nkengasong JN.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):911-7. doi: 10.1089/aid.2007.0264.

PMID:
18593341
9.

Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.

Gordon LL, Gharibian D, Chong K, Chun H.

AIDS Patient Care STDS. 2015 Jul;29(7):384-8. doi: 10.1089/apc.2014.0165. Epub 2015 Jun 4.

PMID:
26114665
10.

HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.

Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX.

HIV Clin Trials. 2013 Jan-Feb;14(1):34-44. doi: 10.1410/hct1401-34.

PMID:
23372113
11.

Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.

Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, Dabis F, Anglaret X; Aconda Study Group.

AIDS. 2008 Apr 23;22(7):873-82. doi: 10.1097/QAD.0b013e3282f768f8.

12.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
13.

Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy.

Messou E, Anglaret X, Duvignac J, Konan-N'dri E, Komena E, Gnokoro J, Karcher S, Tanoh A, N'dri-Yoman T, Seyler C.

AIDS. 2010 Jan 2;24(1):93-9. doi: 10.1097/QAD.0b013e32832ec1c3.

14.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
15.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
16.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
17.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

18.

Medium-term probability of success of antiretroviral treatment after early warning signs of treatment failure in West African adults.

Danel C, Gabillard D, Inwoley A, Chaix ML, Toni TD, Moh R, Messou E, Bissagnene E, Salamon R, Eholie S, Anglaret X.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):783-93. doi: 10.1089/aid.2009.0018.

PMID:
19619008
19.

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.

PMID:
14565604
20.

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.

PMID:
17146376

Supplemental Content

Support Center